New dual-target CAR-T therapy takes on hard-to-treat blood cancers
NCT ID NCT07519187
First seen Apr 16, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This early-phase study tests a new CAR-T cell therapy that targets two markers (CD70 and BCMA) on cancer cells. It is for people with plasma cell cancers like multiple myeloma that have come back or not responded to other treatments. The main goals are to check safety and find the right dose in 20 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Western Theater Command of PLA
Chengdu, Chengdu, China
Conditions
Explore the condition pages connected to this study.